Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C5H7NO4.Ca.2H |
| Molecular Weight | 332.3211 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CC(=O)O)[C@@]([H])(C(=O)O)N.C(CC(=O)[O-])[C@@]([H])(C(=O)[O-])N.[Ca+2]
InChI
InChIKey=UMVAYAXXQSFULN-QHTZZOMLSA-L
InChI=1S/2C5H9NO4.Ca/c2*6-3(5(9)10)1-2-4(7)8;/h2*3H,1-2,6H2,(H,7,8)(H,9,10);/q;;+2/p-2/t2*3-;/m00./s1
| Molecular Formula | H |
| Molecular Weight | 1.0079 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H7NO4 |
| Molecular Weight | 145.1136 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24604256http://www.codifa.it/farmaci/e/elmex-gel-dentale-gel-olaflur-e-dectaflur-e-sodio-fluoruro-anticariehttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfCurator's Comment:: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24604256http://www.codifa.it/farmaci/e/elmex-gel-dentale-gel-olaflur-e-dectaflur-e-sodio-fluoruro-anticariehttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdf
Curator's Comment:: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium iodide (chemical formula CaI2) is the ionic compound of calcium and iodine, used in cat food as a source of iodine This colourless deliquescent solid is a salt that is highly soluble in water. Calcium iodide properties are similar to those for related salts, such as calcium chloride. Calcium iodide is also used in photography.
CNS Activity
Originator
Sources: Helvetica Odontologica Acta (1962), 6, (1), 15-20.https://www.ncbi.nlm.nih.gov/pubmed/16960820
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | elmex Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Studies on the calcemic effect of intravenous secretin in humans. | 1975 Jun |
|
| Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. | 2001 Dec 21 |
|
| Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
| Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
| Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
| Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism. | 2001 Nov |
|
| Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
| Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
| Familial intrahepatic cholestasis 1: studies of localization and function. | 2001 Oct |
|
| Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels. | 2001 Oct 12 |
|
| Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
| Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats. | 2002 |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells. | 2002 Feb |
|
| Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. | 2002 Feb |
|
| Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002 Feb 1 |
|
| Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. | 2002 Jan 15 |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
| Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. | 2002 Jul |
|
| Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. | 2002 Jul 5 |
|
| Human kidney diamine oxidase: heterologous expression, purification, and characterization. | 2002 Jun |
|
| Expression of functional CCR and CXCR chemokine receptors in podocytes. | 2002 Jun 15 |
|
| Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. | 2002 Mar |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
| Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002 Mar 15 |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
| Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit. | 2002 Sep |
|
| Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002 Sep 15 |
|
| Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death. | 2002 Sep 6 |
|
| A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs. | 2002 Sep 6 |
|
| Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension. | 2003 Jan |
|
| An improved method for emergent decontamination of ocular and dermal hydrofluoric acid splashes. | 2004 Aug |
|
| Epidemiology of 377 patients with chemical burns in Guangdong province. | 2004 Sep |
|
| [Prevention of osteoporosis by foods and dietary supplements. Bioavailability of milk micellar calcium phosphate]. | 2006 Oct |
|
| Henri Moissan: winner of the Nobel Prize for Chemistry 1906. | 2006 Oct 20 |
|
| Successful extracorporeal life support after potentially fatal pulmonary oedema caused by inhalation of nitric and hydrofluoric acid fumes. | 2007 Oct |
|
| Dietary calcium source influences body composition, glucose metabolism and hormone levels in a mouse model of postmenopausal obesity. | 2009 Jul-Aug |
|
| A combination of calcium phosphate and probiotics beneficially influences intestinal lactobacilli and cholesterol metabolism in humans. | 2012 Apr |
|
| Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. | 2013 Jan |
|
| Effect of calcium phosphate and vitamin D₃ supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron. | 2014 Jan 17 |
|
| Long-term remineralizing effect of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on early caries lesions in vivo: a systematic review. | 2014 Jul |
|
| Oleylamine as a beneficial agent for the synthesis of CoFe₂O₄ nanoparticles with potential biomedical uses. | 2014 May 7 |
|
| Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model--a clinical trial. | 2015 Aug 12 |
|
| Cytotoxicity of organic surface coating agents used for nanoparticles synthesis and stability. | 2015 Jun |
|
| Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
|
| Lactose behaviour in the presence of lactic acid and calcium. | 2016 Aug |
|
| Allergic contact cheilitis caused by olaflur in toothpaste. | 2017 Jan |
|
| Effects of ultrasound treatment on physico-chemical, functional properties and antioxidant activity of whey protein isolate in the presence of calcium lactate. | 2018 Mar |
Patents
Sample Use Guides
Cytotoxicity study: it was explored the cytotoxicity of the coating agent, Oleylamine in two cell lines, human epidermal keratinocyte (HaCaT) and lung fibroblast (CRL-1490) cells, at surface coating agent concentrations of 3, 10, 30, and 100 μM. Two exposure time points, 2 h, and 24 h were employed for the study. Oleylamine, is highly toxic, leading to almost 100% cell death.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 02:20:41 UTC 2021
by
admin
on
Sat Jun 26 02:20:41 UTC 2021
|
| Record UNII |
9FA5OTO85L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
JECFA EVALUATION |
INS-623
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-623
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C1505
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
CONCEPT | Dietary Supplement | ||
|
CALCIUM DIGLUTAMATE
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
PRIMARY | |||
|
227-838-1
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
PRIMARY | |||
|
C83575
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
PRIMARY | |||
|
9FA5OTO85L
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
PRIMARY | |||
|
5996-22-5
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
PRIMARY | |||
|
INS-623
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
PRIMARY | CAS# 19238-49-4 given in JECFA is for uncertain chemistry ,not for chemical name as called for in JECFA code. | ||
|
SUB13177MIG
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
PRIMARY | |||
|
56841881
Created by
admin on Sat Jun 26 02:20:42 UTC 2021 , Edited by admin on Sat Jun 26 02:20:42 UTC 2021
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
